John W. Walsh Alpha-1 Home Infusion Act of 2025
Latest action: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. · Mar 25, 2025
View full text on Congress.gov ↗ Policy area: Health
John W. Walsh Alpha-1 Home Infusion Act of 2025 This bill provides for Medicare coverage of treatment for alpha-1 antitrypsin (AAT) deficiency (a protein deficiency that raises the risk of lung and other diseases). Specifically, the bill provides for coverage of at-home augmentation therapy for beneficiaries with emphysema as a result of severe hereditary AAT deficiency. Treatment must be provided through qualified home infusion therapy suppliers; beneficiaries must be under the care of a physician, nurse practitioner, or physician assistant.
Source: Congressional Research Service (CRS).
Track HR 2343 in BallotBox360
Get real-time bill updates, floor vote alerts, and AI-powered summaries — all in one app.
Download on iOS Open Web App